Economic burden of pulmonary hypertension. Systematic review
https://doi.org/10.15829/1560-4071-2024-5890
EDN: ISIDTO
Abstract
Aim. A systematic review of studies on pulmonary hypertension (PH) cost estimates.
Material and methods. A systematic literature search was performed for studies assessing the cost of PH published up to November 30, 2023. The search was carried out in the PubMed/MEDLINE, EMBACE databases for publications in English and in the RSCI database for articles in Russian according to inclusion and exclusion criteria.
Results. The systematic review included 13 studies. The mean direct costs per patient with PH after verification of the diagnosis per month ranged from 2023 to 9915 USD, while the median from 1141,5 to 8144 USD. Indirect costs were assessed in only 3 following studies: in Spain and USA, the mean indirect costs were 214 and 1226 USD per patient per month, respectively, while in Russia the median was 65 USD. The mean direct costs per patient with PH per month before diagnosis verification ranged from 1017 to 9723 USD. Indirect costs before diagnosis verification were assessed in only 1 study (median $102 per patient per month). After PH verification, in general, there was an increase in treatment costs with a decrease in other direct costs.
Conclusion. PH causes great socio-economic damage to society and healthcare system. A decrease in non-drug therapy costs after PH verification may indicate not only the clinical effectiveness of PH-specific therapy, but also its potential costeffectiveness with reduced costs.
About the Authors
V. D. Zakiev
Pirogov Russian National Research Medical University — Russian Gerontology Research and Clinical Center
Russian Federation
Russian Federation
Moscow
T. V. Martynyuk
Chazov National Medical Research Center of Cardiology;
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
Yu. V. Kotovskaya
Pirogov Russian National Research Medical University — Russian Gerontology Research and Clinical Center
Russian Federation
Russian Federation
Moscow
References
1. Humbert M, Kovacs G, Hoeper MM, et al.; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1):2200879. doi:10.1183/13993003.00879-2022.
2. Andre P, Joshi SR, Briscoe SD, et al. Therapeutic Approaches for Treating Pulmonary Arterial Hypertension by Correcting Imbalanced TGF-β Superfamily Signaling. Front Med (Lausanne). 2022;8:814222. doi:10.3389/fmed.2021.814222.
3. McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. J Am Coll Cardiol. 2015;65(18):1976-97. doi:10.1016/j.jacc.2015.03.540.
4. Chazova IE, Martynyuk TV, Valieva ZS, et al. Eurasian clinical guidelines on diagnosis and treatment of pulmonary hypertension. Eurasian heart journal. 2020;(1):78-122. (In Russ.) doi:10.38109/2225-1685-2020-1-78-122.
5. D'Alto M, Dimopoulos K, Coghlan JG, et al. Right Heart Catheterization for the Diagnosis of Pulmonary Hypertension: Controversies and Practical Issues. Heart Fail Clin. 2018; 14(3):467-77. doi:10.1016/j.hfc.2018.03.011.
6. Gonzalez-Hermosillo LM, Cueto-Robledo G, Roldan-Valadez E, et al. Right Heart Catheterization (RHC): A Comprehensive Review of Provocation Tests and Hepatic Hemodynamics in Patients With Pulmonary Hypertension (PH). Curr Probl Cardiol. 2022; 47(12):101351. doi:10.1016/j.cpcardiol.2022.101351.
7. Leber L, Beaudet A, Muller A.Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulm Circ. 2021;11(1):2045894020977300. doi:10.1177/2045894020977300.
8. Spaczyńska M, Rocha SF, Oliver E.Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies. ACS Pharmacol Transl Sci. 2020; 3(4):598-612. doi:10.1021/acsptsci.0c00048.
9. Halliday SJ, Hemnes AR, Robbins IM, et al. Prognostic value of acute vasodilator response in pulmonary arterial hypertension: beyond the "classic" responders. J Heart Lung Transplant. 2015;34(3):312-8. doi:10.1016/j.healun.2014.10.003.
10. Zakiev VD, Martynyuk TV, Kotovskaya YV, et al. Features of treatment, hospitalization and working ability of newly diagnosed patients with pulmonary arterial hypertension before and after diagnosis verification. Arterial'naya Gipertenziya = Arterial Hypertension. 2024;30(3):258-71. (In Russ.) doi:10.18705/1607-419X-2024-2404.
11. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023-30. doi:10.1164/rccm.200510-1668OC.
12. Strange G, Gabbay E, Kermeen F, et al. Time from symptoms to definitive diagnosis of idiopathic pulmonary arterial hypertension: The delay study. Pulm Circ. 2013;3(1):89-94. doi:10.4103/2045-8932.109919.
13. Brown LM, Chen H, Halpern S, et al. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest. 2011;140(1):19-26. doi:10.1378/chest.10-1166.
14. Kolbin AS, Zyryanov SK, Belousov DYu. Basic concepts in medical technology assessment. Moscow: OKI Publishing House, 2013. p.42 (In Russ.)
15. Zakiev VD, Gvozdeva AD, Martynyuk TV. Socio-economic burden of pulmonary hypertension: relevance of assessment in Russia and the world. Therapeutic Archive. 2020;92(4):125-31. (In Russ.) doi:10.26442/00403660.2020.03.000591.
16. Wilkens H, Grimminger F, Hoeper M, et al. Burden of pulmonary arterial hypertension in Germany. Respir Med. 2010;104(6):902-10. doi:10.1016/j.rmed.2010.01.002.
17. Angalakuditi M, Edgell E, Beardsworth A, et al. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States. J Med Econ. 2010;13(3):393-402. doi:10.3111/13696998.2010.496694.
18. Kirson NY, Birnbaum HG, Ivanova JI, et al. Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population. Appl Health Econ Health Policy. 2011;9(5):293-303. doi:10.2165/11592430-000000000-00000.
19. Said Q, Martin BC, Joish VN, et al. The cost to managed care of managing pulmonary hypertension. J Med Econ. 2012;15(3):500-8. doi:10.3111/13696998.2012.665109.
20. Copher R, Cerulli A, Watkins A, Laura Monsalvo M.Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States. J Med Econ. 2012;15(5):947-55. doi:10.3111/13696998.2012.690801.
21. Berger A, Edelsberg J, Teal S, et al. Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study. BMC Pulm Med. 2012;12:75. doi:10.1186/1471-2466-12-75.
22. Sikirica M, Iorga SR, Bancroft T, Potash J.The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients. BMC Health Serv Res. 2014;14:676. doi:10.1186/s12913-014-0676-0.
23. Vaid HM, Camacho X, Granton JT, et al. The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario. Can Respir J. 2016;2016:6279250. doi:10.1155/2016/6279250.
24. Dufour R, Pruett J, Hu N, et al. Healthcare resource utilization and costs for patients with pulmonary arterial hypertension: real-world documentation of functional class. J Med Econ. 2017;20(11):1178-86. doi:10.1080/13696998.2017.1363049.
25. Burger CD, Ozbay AB, Lazarus HM, et al. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States. J Manag Care Spec Pharm. 2018;24(8):834-42. doi:10.18553/jmcp.2018.17391.
26. Zozaya N, Abdalla F, Casado Moreno I, et al. The economic burden of pulmonary arterial hypertension in Spain. BMC Pulm Med. 2022;22(1):105. doi:10.1186/s12890-022-01906-2.
27. Ogbomo A, Tsang Y, Mallampati R, Panjabi S.The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States. J Manag Care Spec Pharm. 2022;28(6):608-16. doi:10.18553/jmcp.2022.28.6.608.
28. Zakiev VD, Martynyuk TV, Vedernikov AA, et al. Socio-economic burden of newly diagnosed pulmonary arterial hypertension and early specific treatment initiation impact on the costs in real clinical practice in Russia. Medical Technologies. Assessment and Choice. 2023;(1):99-113. (In Russ.) doi:10.17116/medtech20234501199.
29. Galiè N, Barbera JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373:834-44. doi:10.1056/NEJMoa1413687.
30. Hoeper MM, McLaughlin VV, Barbera JA, et al. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respir Med. 2016;4:894-901. doi:10.1016/S2213-2600(16)30307-1.
31. Vachiéry JL, Galiè N, Barberá JA, et al.; AMBITION Study Group. Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial. J Heart Lung Transplant. 2019;38(2):194-202. doi:10.1016/j.healun.2018.11.006.
32. Galiè N, Humbert M, Vachiéry JL, et al. ESC Scientific Document Group. 2015 ESC/ ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119. doi:10.1093/eurheartj/ehv317.
33. Channick RN, Delcroix M, Ghofrani HA, et al. Effect of macitentan on hospitalizations: results from the SERAPHIN trial. JACC Heart Fail. 2015;3(1):1-8. doi:10.1016/j.jchf.2014.07.013.
34. Yang X, Sanders KN, Mardekian J, et al. Associations Between Sildenafil Use and Changes in Days of Hospitalization in a Population With Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. Clin Ther. 2015;37(5):1055-63. doi:10.1016/j.clinthera.2015.02.025.
35. Sitbon O, Channick R, Chin KM, et al.; GRIPHON Investigators. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015;373(26):2522-33. doi:10.1056/NEJMoa1503184.
36. Figueroa JF, Papanicolas I, Riley K, et al. International comparison of health spending and utilization among people with complex multimorbidity. Health Serv Res. 2021;56 Suppl 3(Suppl 3):1317-34. doi:10.1111/1475-6773.13708.
37. Cantres-Fonseca O, Kennedy JLW. Where's the Easy Button? The Many Barriers to Care for Patients With Pulmonary Arterial Hypertension. J Am Heart Assoc. 2022;11(22):e027967. doi:10.1161/JAHA.122.027967.
38. Khera R, Valero-Elizondo J, Das SR, et al. Cost-Related Medication Nonadherence in Adults With Atherosclerotic Cardiovascular Disease in the United States, 2013 to 2017. Circulation. 2019;140(25):2067-75. doi:10.1161/CIRCULATIONAHA.119.041974.
39. Choudhry NK, Avorn J, Glynn RJ, et al. Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) Trial. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365:2088-97. doi:10.1056/NEJMsa1107913.
Supplementary files
Review
For citations:
Zakiev V.D., Martynyuk T.V., Kotovskaya Yu.V. Economic burden of pulmonary hypertension. Systematic review. Russian Journal of Cardiology. 2024;29(3S):5890. (In Russ.) https://doi.org/10.15829/1560-4071-2024-5890. EDN: ISIDTO
Views: 123
Email this article 